, 2004), peptidoglycan ( Verbrugh et al., 1981) and lipoteichoic acid ( Wergeland et al., 1984), are also known to be immunogenic. In future studies we will include the analysis of the host response against these cell-wall components as well. Moreover, next to IgG levels, other immunoglobulins and their subclasses will be investigated. The authors do not have a commercial or other association that might pose a conflict of interest. We thank D.G.A.M. Koedijk for purification of Nuc, LytM, and IsaA. We thank G. Buist, T. Bosma, T. Foster, J.I. Epigenetic inhibitor solubility dmso Flock,

S. Rooijkakkers, S. Holtfreter, D. Grumann, and J.D. Fraser for kindly supplying the S. aureus proteins. S.v.d.B., T.B., G.B., J.M.v.D., A.v.B. and I.B.-W. were in part supported financially by the Top Institute Pharma project

T4-213. ”
“Salmonella enterica causes a spectrum of diseases, including typhoid and paratyphoid fever, and gastroenteritis ( Everest et al., 2001, Hohmann, 2001 and Boyle et al., 2007), and is a major threat to public health. S. enterica PARP inhibitors clinical trials serovar Typhi is the causative agent of typhoid fever. Paratyphoid fever, a clinically-similar disease with less prevalence, is caused by S. enterica serovar Paratyphi A, B and C. In developed countries, nontyphoidal isolates of Salmonella (NTS) usually cause gastroenteritis. In Africa, NTS, especially S. enterica serovar Typhimurium, are a common cause of invasive disease, in particular bacteremia. NTS bacteremia in sub-Saharan Africa primarily occurs in children under 2 years of age and HIV-infected individuals ( Graham et al., 2000, Graham, 2002, Graham, 2010, Brent et al., 2006 and Bronzan et al., 2007). The estimated minimum incidence of NTS bacteremia is 175 per 100,000 in Kenyan children under 5 years of age

per year ( Berkley et al., 2005). The lack of specific clinical presentation of NTS bacteremia makes diagnosis difficult. In addition, increased drug resistance and the emergence of new multi-drug resistant isolates ( Hohmann, 2001 and Mirza et al., 1996) have added to the burden of this often fatal disease. These findings emphasize the need for an effective vaccine against NTS. Currently, none is available for use in humans. The role of antibody in protection against Cepharanthine Salmonella has been well established. Adoptive transfer of antibodies confers protection against virulent Salmonella challenge ( Mastroeni et al., 1993 and McSorley and Jenkins, 2000). The importance of antibodies has also been emphasized by studies on Vi polysaccharide, which elicit T cell-independent antibody production and confer protection ( Acharya et al., 1987). A key assessment of most vaccines is their ability to induce specific antibody production. However, high antibody levels alone are insufficient, since vaccine-induced antibodies need to be protective.